Michelle Tran‐Dubé

Author

Michelle Tran‐Dubé

Also Known As

Michelle B. Tran-Dubé, Michelle B. Tran‐Dube, Michelle Tran-Dube, Michelle Tran-Dubé, Michelle Tran‐Dube, Michelle Tran‐Dubé, Tran-Dube, M., Tran-Dube, M.B., Tran-Dubé, Michelle, Tran-Dubé, Michelle

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Université Bourgogne Franche-Comté Scripps Research Institute University of Pittsburgh

About

Michelle Tran‐Dubé is an author at Pfizer (United States) specializing in organic chemistry, chemistry, and catalysis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	4	4	207
2	Biochemistry	4	4	1.1K
3	Medicine	3	3	979
4	Natural Sciences	3	3	1.1K
5	Health Sciences	1	1	35

Michelle Tran‐Dubé

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) J. Jean Cui, Michelle Tran‐Dubé, Hong Shen, Journal of Medicinal Chemistry Drug TargetLead SeriesChemical BiologyAnaplastic Lymphoma KinasePharmaceutical Chemistry	2011	905
A peptide-catalyzed asymmetric Stetter reaction Steven M. Mennen, Jarred T. Blank, Michelle Tran‐Dubé, Chemical Communications Intramolecular Stetter ReactionTest SubstrateNovel OrganocatalystsEngineeringHeterocyclic	2004	134
Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1 <i>H</i> -[1,2,3]triazolo[4,5- <i>b</i> ]pyrazin-6-yl)-1 <i>H</i> -pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer J. Jean Cui, Michele McTigue, Mitchell D. Nambu, Journal of Medicinal Chemistry	2012	103
Anti-selective [3+2] (Hetero)annulation of non-conjugated alkenes via directed nucleopalladation Hui‐Qi Ni, Ilia Kevlishvili, Pranali G. Bedekar, Nature Communications	2020	61
Lessons from (<i>S</i>)-6-(1-(6-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats J. Jean Cui, Hong Shen, Michelle Tran‐Dubé, Journal of Medicinal Chemistry Compound 8Chemoprevention StrategyCardiovascular PharmacologyCell DeathCellular Pharmacology	2013	39
Synthesis of Aryl Ethers via a Sulfonyl Transfer Reaction Neal W. Sach, Daniel T. Richter, Stephan J. Cripps, Organic Letters Cross-coupling ReactionAryl EthersEngineeringAlkene MetathesisOrganic Chemistry	2012	37
Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain Sharan K. Bagal, Mark D. Andrews, Bruce M. Bechle, Journal of Medicinal Chemistry Drug TargetPain MedicineMolecular PainPharmacotherapyPharmaceutical Chemistry	2018	35
Copper-Catalyzed Chan–Lam Cyclopropylation of Phenols and Azaheterocycles Joseph Derosa, Miriam L. O’Duill, Matthew Holcomb, The Journal of Organic Chemistry	2018	34
Rhodium(III)-Catalyzed C–H Activation: Ligand-Controlled Regioselective Synthesis of 4-Methyl-Substituted Dihydroisoquinolones Joyann S. Barber, Stephanie Scales, Michelle Tran‐Dubé, Organic Letters	2019	33
Cu-Catalyzed Hydroboration of Benzylidenecyclopropanes: Reaction Optimization, (Hetero)Aryl Scope, and Origins of Pathway Selectivity Jose M. Medina, Taeho Kang, Tuğçe G. Erbay, ACS Catalysis	2019	33

Page 1